Matthew Vesely, MD, PhD
Assistant Professor of DermatologyCards
Publications Overview
- 61 Publications
- 6,588 Citations
- 45 Yale Co-Authors
Vesely lab
About
Titles
Assistant Professor of Dermatology
Biography
I am a physician-scientist with specialized training in immunology, molecular biology, genetics, and clinical dermatology. My career is dedicated to integrating fundamental immunology with clinical dermatology, with a particular focus on the role of costimulatory and inhibitory immune receptors in cancer immunity, autoimmune pathogenesis, and immunotherapy.
My interest in this field was shaped during my training in the Medical Scientist Training Program at Washington University in St. Louis, where I conducted research in the laboratory of Dr. Robert Schreiber, investigating key molecular regulators of cancer immunoediting. This experience, combined with my growing expertise in skin immunology and the evolution of immunotherapies for melanoma, ultimately led me to pursue a career in dermatology.
During my dermatology residency at Yale School of Medicine, I had the opportunity to further expand my research in immune checkpoint pathways under the mentorship of Dr. Lieping Chen, a pioneer in PD-1 axis-targeted cancer immunotherapy. This work deepened my focus on novel immune regulatory mechanisms, including programmed death receptor-1 homolog (PD-1H), also known as VISTA.
My current research focuses on:
- Identifying novel immune checkpoints, such as PD-1H/VISTA, in cutaneous malignancies (e.g., melanoma and keratinocyte carcinomas).
- Elucidating the inhibitory immune landscape of chronic inflammatory skin disorders, including psoriasis, eczema, lichen planus and cutaneous lupus erythematosus.
Through my research and clinical work, I strive to bridge the gap between immune system regulation and dermatologic disease, ultimately contributing to the development of new immunotherapeutic strategies for cancer and inflammatory skin conditions.
Appointments
Dermatology
Assistant ProfessorPrimary
Other Departments & Organizations
- Autoimmune Skin Disease Program
- Cancer Immunology
- Chen Lab
- Dermatology
- Human and Translational Immunology Program
- Janeway Society
- Psoriasis Treatment Program
- Vesely Lab
- Yale Cancer Center
- Yale Medicine
Education & Training
- Resident
- Yale School of Medicine (Dermatology) (2014-2017) (2017)
- Intern
- Barnes Jewish Hospital (St. Louis) (2013-2014) (2014)
- PhD
- Washington University School of Medicine, St. Louis, Immunology (2013)
- MD
- Washington University School of Medicine (2013)
- BS
- Creighton University, Biology, Theology, History (2003)
Research
Overview
The Vesely Lab is dedicated to investigating the role of immune inhibitory receptors, often referred to as immune checkpoints, in autoimmune skin diseases and skin cancer. Our research leverages cutting-edge technologies, including spatial proteomics and transcriptomics, to analyze both human patient samples and mouse models of disease, enabling us to decipher key inflammatory pathways driving these conditions.
Our primary areas of focus include:
- Autoimmune skin diseases such as cutaneous lupus erythematosus and lichen planus, which currently lack FDA-approved therapies.
- Chronic inflammatory skin conditions like psoriasis and atopic dermatitis, where additional therapeutic options are needed.
- Cancer immune evasion mechanisms in melanoma and cutaneous squamous cell carcinoma, with the goal of uncovering novel immunoregulatory pathways.
By visualizing immune regulatory patterns in both cutaneous autoimmunity and malignancies, our ultimate goal is to identify new therapeutic targets that can lead to more effective treatments for these complex dermatologic conditions.
Medical Research Interests
Public Health Interests
ORCID
0000-0001-9363-945XVesely lab
Harnessing immune regulation for the treatment of cancer and autoimmunity
View Lab Website
Research at a Glance
Publications Timeline
Yale Co-Authors
Research Interests
Jacky Yeung, MD, FAANS
Lieping Chen, MD, PhD
Michal Kidacki, MD, PhD
Christina Cho, PhD
Danielle Miyagishima, PhD
Francesc Lopez-Giraldez, PhD
Lupus Erythematosus, Cutaneous
Melanoma
Psoriasis
Skin
Carcinoma, Squamous Cell
Publications
Featured Publications
PD-1H (VISTA) expression in cutaneous squamous cell carcinoma is correlated with T cell infiltration and activation
Kidacki M, Cho C, Lopez-Giraldez F, Huang B, He J, Gaule P, Chen L, Vesely M. PD-1H (VISTA) expression in cutaneous squamous cell carcinoma is correlated with T cell infiltration and activation. Journal Of Investigative Dermatology 2025 PMID: 39983979, DOI: 10.1016/j.jid.2025.01.030.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaPD-L1 expressionT cell infiltrationPD-L1Squamous cell carcinomaVISTA expressionPD-1HCell carcinomaT cellsBlockade of PD-1Proliferation marker Ki-67Multiplexed quantitative immunofluorescencePD-L1 coexpressionTreatment of cutaneous squamous cell carcinomaControl T cellsPreclinical cancer studiesMyeloid cell functionImmunosuppressive microenvironmentPD-1Receptor antagonismKi-67Individual tumorsGranzyme B.Clinical trialsCancer clinical trialsImmune Checkpoint Agonists for Inflammatory Skin Diseases
Vesely M, Lizzul P, Klekotka P, Joller N, Raff A. Immune Checkpoint Agonists for Inflammatory Skin Diseases. Journal Of Investigative Dermatology 2025 PMID: 39927905, DOI: 10.1016/j.jid.2025.01.008.Peer-Reviewed Original ResearchSpatial Transcriptomics in Inflammatory Skin Diseases Using GeoMx Digital Spatial Profiling: A Practical Guide for Applications in Dermatology
Cho C, Haddadi N, Kidacki M, Woodard G, Shakiba S, Yıldız-Altay Ü, Richmond J, Vesely M. Spatial Transcriptomics in Inflammatory Skin Diseases Using GeoMx Digital Spatial Profiling: A Practical Guide for Applications in Dermatology. JID Innovations 2024, 5: 100317. PMID: 39559817, PMCID: PMC11570843, DOI: 10.1016/j.xjidi.2024.100317.Peer-Reviewed Original ResearchConceptsDigital spatial profilingInflammatory skin diseaseGeoMx Digital Spatial ProfilerSkin diseasesDiscoid lupus erythematosusNanoString GeoMx Digital Spatial ProfilingImmune milieuImmune microenvironmentLichen planusLupus erythematosusSingle cell RNA sequencingAberrant inflammationCell RNA sequencingSkin disease pathogenesisDisease pathogenesisManufacturer's guidelinesIndicators of diseaseDiseaseSpatial transcriptomics platformSkinTissue processingImmune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
Vesely M, Kidacki M, Gaule P, Gupta S, Chan N, Han X, Yeung J, Chen L. Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes. Journal Of Investigative Dermatology 2023, 144: 106-115.e4. PMID: 37562584, DOI: 10.1016/j.jid.2023.07.008.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsCD11b myeloid cellsImmune inhibitory moleculesPD-L1 expressionVISTA expressionMyeloid cellsFuture potential therapeutic targetsPD-L1/B7Tumor microenvironmentInhibitory moleculesMultiplexed quantitative immunofluorescencePrimary cutaneous melanomaImmunosuppressive tumor microenvironmentNegative prognostic biomarkerCurrent clinical trialsPotential therapeutic targetCause mortalityCritical cell typesPD-L1Poor outcomeTreatment of cancerMelanoma recurrenceCutaneous melanomaClinical trialsPrognostic biomarkerT cellsResistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review Of Immunology 2022, 40: 45-74. PMID: 35471840, DOI: 10.1146/annurev-immunol-070621-030155.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH Keywords and ConceptsConceptsAnti-PD therapyCancer immunotherapyMechanisms of resistanceImmune inhibitory moleculesFraction of patientsResistance mechanismsNormalization cancer immunotherapyAdditional immunotherapyPD-1Clinical evidenceAntigen presentationT cellsSolid tumorsTherapy resistanceH1 pathwayTumor microenvironmentImmunotherapyInhibitory moleculesHematopoietic malignanciesCancer treatmentTherapyPatientsCurrent studyCancer dataMalignancyPD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Han X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, López-Giráldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Flies DB, Zheng L, Kim TK, Moeckel GW, McNiff JM, Chen L. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine 2019, 11 PMID: 31826980, DOI: 10.1126/scitranslmed.aax1159.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsMeSH KeywordsAnimalsArthritisAutoantibodiesAutoimmunityDendritic CellsHumansInflammationInterferon Type ILupus Erythematosus, CutaneousLupus Erythematosus, SystemicMembrane ProteinsMice, Inbred BALB CMice, Inbred MRL lprMyeloid CellsNeutrophilsReceptors, Antigen, T-CellSignal TransductionTerpenesUp-RegulationConceptsPlasmacytoid dendritic cellsDiscoid lupus erythematosusSystemic lupus erythematosusCutaneous lupus lesionsPD-1HLupus erythematosusLupus lesionsAutoimmune diseasesKO miceT cellsMyeloid cellsHuman systemic lupus erythematosusBALB/c backgroundCutaneous lupus erythematosusInappropriate immune responseProgression of lupusSystemic autoimmune diseaseImmune cell expansionSuppression of autoimmunityAgonistic monoclonal antibodyDeath-1 homologCutaneous lupusProinflammatory neutrophilsDendritic cellsDLE lesionsCutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.
Little AJ, Vesely MD. Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. The Yale Journal Of Biology And Medicine 2020, 93: 81-95. PMID: 32226339, PMCID: PMC7087060.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH Keywords and ConceptsConceptsCutaneous lupus erythematosusDevelopment of CLEDisease pathogenesisAdaptive immune componentsClinical trial landscapeUnmet medical needFuture therapeutic strategiesPromising clinical trialsFuture pathogenesisLupus erythematosusSignificant morbidityAutoimmune diseasesImmune cellsClinical trialsCurrent treatmentTrial landscapeImmune componentsTherapeutic strategiesDrug AdministrationMedical needDiseasePathogenesisEnvironmental triggersTherapyType ICancer Immunoediting in the Era of Immuno-oncology.
Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research 2022, 28: 3917-3928. PMID: 35594163, PMCID: PMC9481657, DOI: 10.1158/1078-0432.ccr-21-1804.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH Keywords and ConceptsConceptsCancer immunoeditingImmune-tumor cell interactionsCancer immunotherapyAbsence of immunotherapyDurable clinical responsesT cell biologyCell interactionsImmunotherapy resistanceClinical responseImmunosuppressive microenvironmentTumor immunogenicityImmuno-oncologyClinical dataPreclinical modelsImmunoeditingImmunotherapyHuman patientsImmune systemTumor microenvironmentCancerCancer progressionClinical subspecialtyImmunogenicityMicroenvironmentPatientsTreatment of cutaneous lupus with topical ruxolitinib cream
Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Reports 2022, 28: 133-135. PMID: 36159722, PMCID: PMC9494033, DOI: 10.1016/j.jdcr.2022.08.038.Peer-Reviewed Case Reports and Technical NotesClinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
Noelle R, Lines J, Lewis L, Martell R, Guillaudeux T, Lee S, Mahoney K, Vesely M, Boyd-Kirkup J, Nambiar D, Scott A. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Frontiers In Oncology 2023, 13: 1225081. PMID: 37795437, PMCID: PMC10547146, DOI: 10.3389/fonc.2023.1225081.Commentaries, Editorials and LettersConceptsImmune checkpoint proteinsImmune checkpointsImmune systemT-lymphocyte antigen-4Cell death protein 1V-domain immunoglobulin suppressorDeath protein 1CD28 family membersAnti-VISTA antibodyT cell activationImportant homeostatic functionsVISTA blockadePD-1Proinflammatory changesImmune effectsMyeloid suppressionAntigen-4CTLA-4Immune cellsT cellsImmune responsePreclinical studiesClinical developmentHomeostatic functionsMyeloid lineage
Clinical Care
Are You a Patient?
Please visit the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileRelated Yale Medicine Content
41 Condition Fact Sheets4 Clinical Departments44 News ArticlesSee All Related Content on Yale Medicine
Overview
Matthew Vesely, MD, is a dermatologist who treats psoriasis, eczema, and other autoimmune skin disorders. Dr. Vesely also sees patients with chronic skin diseases, including discoid lupus erythematosus (DLE) and hidradenitis suppurativa (HS).
“Seeing patients who have been suffering from inflammatory skin diseases for years finally get relief with the help of a targeted therapy is very rewarding,” he says.
Dr. Vesely says he enjoys working with patients and their families to find the best approach to treat a skin disorder. “I always explain that even if the first set of therapies are ineffective, we won't stop until we find the most effective treatment plan,” he says.
Dr. Vesely says he chose his specialty after learning that a large number of skin diseases caused by an overactive immune system lack FDA-approved treatments. In his research, Dr. Vesely investigates emerging new therapies that could potentially help his patients.
“Being able to research the same diseases I treat is extremely gratifying and motivating,” Dr. Vesely says.
Clinical Specialties
Fact Sheets
Lichen Planus
Learn More on Yale MedicinePsoriasis
Learn More on Yale MedicineAlopecia Areata
Learn More on Yale MedicineRosacea
Learn More on Yale Medicine
Board Certifications
Dermatology
- Certification Organization
- AB of Dermatology
- Original Certification Date
- 2017
Yale Medicine News
Academic Achievements & Community Involvement
activity American Academy of Dermatology
Professional OrganizationsFellowDetails07/01/2018 - Presentactivity Lancet, Nature Cancer, International Journal of Dermatology, Journal of Investigative Dermatology, JAAD Case Reports, Journal of European Academy of Dermatology and Venerology, Frontiers in Oncology, Frontiers in Immunology, Cancers
Journal ServiceReviewerDetails06/01/2015 - Presentactivity Lupus Research Alliance
Peer Review Groups and Grant Study SectionsGrant ReviewerDetails06/01/2022 - Presentactivity Society for Investigative Dermatology
Professional OrganizationsMemberDetails07/01/2014 - Presentactivity Medical Dermatology Society
Professional OrganizationsMemberDetails07/01/2014 - Present
Links
Media
- PD-1H (VISTA) expression (green) is more abundant in human cutaneous lupus (right) than normal skin (left) and co-localizes with CD3 T cells (red).
Get In Touch
Contacts
Dermatology
333 Cedar Street, LMP 5040, PO Box 208059
New Haven, CT 06520-8059
United States
Administrative Support
Locations
Dermatology
Academic Office
Hunter Building
15 York Street, Rm HRT 603B
New Haven, CT 06510
Chen Lab
Lab
West Campus Molecular Innovations Center
600 West Campus Drive
West Haven, CT 06516
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
- Organization Only
- Organization Only
- Organization Only
- Organization Only